Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of C5a and C5aR. C5a is a powerful inflammatory mediator involved in a wide variety of autoimmune and other inflammatory diseases. The company's lead product candidate, vilobelimab, is a novel intravenously administered first-in-class monoclonal anti-C5a antibody, which has demonstrated activity in various disease settings, including emergency use authorization in the US for critically ill COVID-19 patients. InflaRx is also developing other C5a/C5aR inhibitors for various indications.
Serves as the global operational and research & development hub, overseeing clinical trial management, drug discovery, corporate strategy, and administrative functions.
Located in Jena, a city renowned as a German center for optics, life sciences, and research (BioRegio Jena), providing access to a skilled talent pool and collaborative opportunities with universities and research institutions. The facility likely includes modern office spaces and potentially laboratory facilities.
A science-driven, innovative, and collaborative environment focused on advancing novel therapeutics. The culture likely emphasizes meticulous research, teamwork across disciplines (R&D, clinical, regulatory), and a shared mission to address severe inflammatory conditions.
The Jena headquarters is pivotal for InflaRx's core R&D activities, intellectual property development, and strategic decision-making. Its location in Germany leverages the country's strong biopharmaceutical infrastructure and scientific talent.
InflaRx operates with a global strategic focus, primarily centered in Europe and North America. Its R&D and corporate headquarters are in Jena, Germany, while its U.S. subsidiary in Ann Arbor, Michigan, supports clinical development, regulatory affairs, and business operations in the U.S. The company conducts multinational clinical trials for its product candidates, engaging with regulatory agencies worldwide.
Winzerlaer Str. 2
Jena
Thuringia
Germany
Address: 2000 Green Road, Suite 200, Ann Arbor, MI 48105, USA
To manage and advance clinical trials within the United States, facilitate regulatory interactions, and support potential future commercialization efforts in the key North American market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, InflaRx' leadership includes:
InflaRx has been backed by several prominent investors over the years, including:
Over the past 12 months (mid-2023 to mid-2024), InflaRx experienced key changes in its executive team, including the departure of its Chief Financial Officer, the appointment of an Interim CFO, and the promotion of its Chief Business Officer to Chief Operating Officer.
Discover the tools InflaRx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
InflaRx likely utilizes standard corporate email formats. Common patterns for companies like InflaRx include [first_initial].[last]@[companydomain].com or [first_name].[last_name]@[companydomain].com. The primary domain is inflarx.com.
[first_initial].[last]@inflarx.com
Format
n.riedemann@inflarx.com
Example
85%
Success rate
InflaRx N.V. / GlobeNewswire • March 27, 2024
InflaRx announced its financial results for the fiscal year ended December 31, 2023, and provided a comprehensive business update. The report highlighted progress in its clinical programs, including vilobelimab, and outlined strategic priorities for future development and potential commercialization....more
InflaRx N.V. / GlobeNewswire • March 18, 2024
InflaRx reported positive topline results from its Phase II IXPLORE study, which evaluated vilobelimab in patients with ANCA-associated vasculitis. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in disease activity for patients treated with vilobelimab plus standard of care compared to placebo plus standard of care....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including InflaRx, are just a search away.